German pharma company Fresenius Kabi has launched Methocarbamol Injection, USP in the US in a 100 mg per mL 10 mL vial presentation.
Methocarbamol Injection, USP is to be used as a supplement to rest, physical therapy, and other measures to ease discomfort caused by acute, painful musculoskeletal conditions. It indicated for only intravenous and intramuscular use.
John Ducker – president and CEO of Fresenius Kabi USA, commenting on the US launch of Methocarbamol Injection, USP, said: “We are pleased to expand our anesthesia and analgesia portfolio with the introduction of Methocarbamol Injection, a medication that can provide relief for people with acute, painful musculoskeletal conditions.”
Methocarbamol Injection, USP is the latest addition to Fresenius Kabi’s portfolio of drugs for anesthesia and analgesia.
In December 2018, Fresenius Kabi launched Omegaven (fish oil triglycerides) injectable emulsion in the US. Omegaven provides calories and fatty acids to pediatric patients suffering from parenteral nutrition-associated cholestasis (PNAC).